These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
579 related articles for article (PubMed ID: 16004682)
1. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Catapano A; Brady WE; King TR; Palmisano J Curr Med Res Opin; 2005 Jul; 21(7):1123-30. PubMed ID: 16004682 [TBL] [Abstract][Full Text] [Related]
2. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864 [TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521 [TBL] [Abstract][Full Text] [Related]
4. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW; Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. Roth EM; McKenney JM; Kelly MT; Setze CM; Carlson DM; Gold A; Stolzenbach JC; Williams LA; Jones PH Am J Cardiovasc Drugs; 2010; 10(3):175-86. PubMed ID: 20524719 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168 [TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR; Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Bays HE; Davidson MH; Massaad R; Flaim D; Lowe RS; Tershakovec AM; Jones-Burton C Am J Cardiol; 2011 Aug; 108(4):523-30. PubMed ID: 21596364 [TBL] [Abstract][Full Text] [Related]
9. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610 [TBL] [Abstract][Full Text] [Related]
10. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Stender S; Schuster H; Barter P; Watkins C; Kallend D; Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130 [TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175 [TBL] [Abstract][Full Text] [Related]
12. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
13. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Bays HE; Averna M; Majul C; Muller-Wieland D; De Pellegrin A; Giezek H; Lee R; Lowe RS; Brudi P; Triscari J; Farnier M Am J Cardiol; 2013 Dec; 112(12):1885-95. PubMed ID: 24063830 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW; Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438 [TBL] [Abstract][Full Text] [Related]
16. Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Vaverkova H; Farnier M; Averna M; Missault L; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Brudi P Clin Biochem; 2011 Jun; 44(8-9):627-34. PubMed ID: 21349260 [TBL] [Abstract][Full Text] [Related]
17. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Farnier M; Volpe M; Massaad R; Davies MJ; Allen C Int J Cardiol; 2005 Jul; 102(2):327-32. PubMed ID: 15982505 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Brown WV; Bays HE; Hassman DR; McKenney J; Chitra R; Hutchinson H; Miller E; Am Heart J; 2002 Dec; 144(6):1036-43. PubMed ID: 12486428 [TBL] [Abstract][Full Text] [Related]
19. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082 [TBL] [Abstract][Full Text] [Related]
20. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P; Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]